LAURUSLABS Q3 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,415 Cr
verified against source
Revenue YoY
18%
reported change
EBITDA
₹285 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs delivered Q3 FY25 revenue of INR 1,415 crore (+18% YoY), with EBITDA margins expanding to 20.1%—a 160bps improvement over 9M FY24—as CDMO momentum accelerates. The CDMO division recorded its highest quarterly sales in eight quarters (~INR 400 crore, +33% YTD), driven by multi-product commercial deliveries and clinical project progression. API revenues declined 7% YoY to INR 531 crore due to lower ARV offtake, though management confirmed the order book remains healthy. Formulation sales of INR 436 crore show recovery with 43 ANDAs filed and 21 approvals. Management retained FY25 EBITDA guidance of ~20% and projects CDMO to drive "better year in FY2026." Key risks include ARV franchise volatility amid WHO policy shifts, pending capacity ramp-up at new facilities, and the BIOSECURE Act's uncertain long-term impact on supply chain diversification momentum.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated full-year EBITDA margin guidance of ~20%, implying H2 margin improvement driven by CDMO ramp-up and operating leverage.
- CEO explicitly stated FY2026 will be a 'better year for CDMO' than FY2025, citing robust pipeline, multiple commercial programs, and animal health growth.
- Laurus Bio's large-scale 2-million-liter fermentation capacity at Vizag expected to be operational by end-CY2026, more than doubling current capacity with Eight Roads as strategic partner.
- Investment of INR 120-130 crore into GMP-scale facility for viral vectors and plasmids CMO, expected operational in FY2026.
Risks flagged
- ARV (API+formulation) contributes ~INR 619 crore quarterly but faces headwinds from U.S. WHO withdrawal impact on guidelines/approvals, PEPFAR tender dynamics, and Global Fund tender cycles expiring in 2026.
- Asset turnover at 0.8x vs 1.4x historical peak indicates significant unmonetized capacity from INR 3,000 crore CapEx; margins suppressed by ongoing operational deleverage.
- Analyst repeatedly requested phase-wise pipeline breakdown (Phase 1/2/3) and commercial molecule count for FY26; management declined citing confidentiality, limiting investor visibility into revenue timing.
- Despite 18-month delay, analyst questioned whether supply chain diversification momentum from big/mid pharma is slowing; management claimed no degrowth in visits or RFP flow but impact remains uncertain.
Key quotes
- The growth came from multiple products, not from one product. Growth came from multiple products, so we're happy that our CDMO division also well-diversified.
- When we go commercial, I think revenues will be somewhere in between [0.8x and 1.4x asset turnover]. The real value comes when we do commercialize.
- We are broadening our pipeline in our API and also in formulations. That will take some time. It will not be a quantum jump in FY2026. But the kind of pipeline we are developing will have unique offerings, and we expect significant growth will come in the medium term.
Research modules